Schneider Downs Wealth Management Advisors LP Has $341,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Schneider Downs Wealth Management Advisors LP lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 47.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 1,476 shares of the company’s stock after purchasing an additional 472 shares during the period. Schneider Downs Wealth Management Advisors LP’s holdings in Eli Lilly and were worth $341,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Atlas Capital Advisors LLC lifted its holdings in Eli Lilly and by 64.6% during the second quarter. Atlas Capital Advisors LLC now owns 107 shares of the company’s stock worth $25,000 after acquiring an additional 42 shares during the period. Penserra Capital Management LLC purchased a new position in shares of Eli Lilly and in the second quarter worth about $33,000. Financial Insights Inc. bought a new stake in Eli Lilly and during the 2nd quarter valued at $36,000. Corsicana & Co. bought a new stake in shares of Eli Lilly and during the 2nd quarter valued at $46,000. Finally, Sierra Capital LLC purchased a new stake in Eli Lilly and in the 1st quarter worth approximately $46,000. Institutional investors own 81.56% of the company’s stock.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 195,000 shares of the business’s stock in a transaction that occurred on Thursday, November 4th. The stock was sold at an average price of $268.82, for a total transaction of $52,419,900.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

LLY has been the subject of several research reports. Morgan Stanley upped their target price on shares of Eli Lilly and from $207.00 to $275.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th. Cowen upped their price target on shares of Eli Lilly and from $250.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, August 30th. Truist lifted their price objective on Eli Lilly and from $262.00 to $301.00 and gave the stock a “buy” rating in a research report on Wednesday. BMO Capital Markets assumed coverage on shares of Eli Lilly and in a research note on Thursday, November 18th. They set an “outperform” rating and a $311.00 target price on the stock. Finally, JPMorgan Chase & Co. reissued a “buy” rating and set a $300.00 price objective on shares of Eli Lilly and in a research report on Friday, September 24th. One research analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $271.11.

LLY stock opened at $262.00 on Thursday. Eli Lilly and Company has a 1 year low of $142.61 and a 1 year high of $275.87. The firm has a market capitalization of $250.63 billion, a PE ratio of 39.94, a price-to-earnings-growth ratio of 2.06 and a beta of 0.32. The business has a 50 day simple moving average of $244.91 and a 200-day simple moving average of $237.93. The company has a debt-to-equity ratio of 1.95, a current ratio of 1.30 and a quick ratio of 1.02.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Monday, October 25th. The company reported $1.94 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.98 by ($0.04). Eli Lilly and had a return on equity of 111.51% and a net margin of 21.52%. The company had revenue of $6.77 billion for the quarter, compared to analysts’ expectations of $6.64 billion. During the same period last year, the business earned $1.54 EPS. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post 8.01 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 10th. Investors of record on Monday, November 15th will be issued a $0.85 dividend. The ex-dividend date is Friday, November 12th. This represents a $3.40 annualized dividend and a yield of 1.30%. Eli Lilly and’s dividend payout ratio (DPR) is 51.83%.

Eli Lilly and Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Featured Article: What is the Rule of 72?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.